bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427392; this version posted January 27, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Itaconate and derivatives reduce interferon responses and inflammation 2 in influenza A virus infection 3 4 Aaqib Sohail1,9*, Azeem A. Iqbal1,9*, Nishika Sahini1,9*, Mohamed Tantawy1,9, Moritz 5 Winterhoff1,9, Thomas Ebensen2 , Robert Geffers3, Klaus Schughart4, Fangfang Chen1,9, Matthias 6 Preusse1,2, Marina C. Pils5, Carlos A. Guzman2, Ahmed Mostafa6, Stephan Pleschka6, Christine 7 Falk7, Alessandro Michelucci8, Frank Pessler1,9,** 8 9 1Biomarkers for Infectious Diseases, 2Vaccinology and Applied Microbiology, 3Genome 10 Analytics, 4Infection Genetics, 5Mouse Pathology Platform, Helmholtz Centre for Infection 11 Research, 31824 Braunschweig, Germany 12 6Institute for Medical Virology, Justus-Liebig-University, 35392 Giessen, Germany 13 7Department of Transplantation Immunology, Hannover Medical School, 30625 Hannover, 14 Germany 15 8Dept. of Oncology, Luxembourg Institute of Health, 1526 Luxembourg 16 9TWINCORE Centre for Experimental and Clinical Infection Research, 30625 Hannover, 17 Germany 18 19 * Joint first authors 20 21 ** Corresponding author 22 Frank Pessler, MD, PhD 23 Tel. +49 511 220027-167, Mobile +49 160 9728 0364 24
[email protected] 25 26 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427392; this version posted January 27, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Itaconate and influenza A virus infection 27 Abstract 28 Itaconate has recently emerged as a metabolite with immunomodulatory properties.